Clinical Trials with Combination of Cytokine-Induced Killer Cells and Dendritic Cells for Cancer Therapy.
Dendritic cells are one of the most powerful weapons in our arsenal against cancer, and the latest research shows that combining d-cells with cytokine-induced killer cells can be an effective treatment. Cytokines such as interleukin 2 (IL2) and granulocyte macrophage colony-stimulating factor (GMCSF) have been used for many years to stimulate natural killer cell activity, but they also have a detrimental effect on healthy tissue. Dendritic cells, which present tumor antigens to T lymphocytes in order to initiate a protective immune response, offer a promising new avenue for cancer therapy.
Immunotherapy is a promising treatment for a number of cancers. CIK cells have a significant antitumor activity and are able to eradicate tumors with few side effects. The differences of the outcomes in different kinds of cancers could result from different molecular mechanisms unexplained yet.
It is estimated that cancer affects 1 in 2 men and women during their lifetime. The D-Cells are the latest weapon in the fight against cancer, combining Cytokine-Induced Killer Cells (CIKs) with dendritic cells for therapy. It has been shown to be effective at treating many types of cancers including melanoma, breast cancer, prostate cancer, lung cancer and leukemia.
The DCT procedure begins by harvesting a person’s own blood stem cells or cord blood from umbilical cord after birth; these are then separated into pure populations of CD34+ hematopoietic progenitor cells and monocytes which can differentiate into macrophages. Next an irradiated antigen presenting
Article Reference link: click here
Scientific article publishing date : 16/6/2019
Immucura identifier : BSC21_010EN